At-Risk Populations
Study will evaluate recombinant canarypox HIV-1 vaccine in IV drug users
Published in Vaccine Weekly, July 2nd, 2003
S. Dhalla announced the clinical trial at the 36th Annual Society of Epidemiological Research (SER) Meeting held in Atlanta, Georgia, June 11-14, 2003.
"The efficacy of a recombinant canarypox ALVAC-vCP205 HIV-1 vaccine will be studied in an initially seronegative group of IV drug users, a disadvantaged community of individuals. Excluded will be those with mental illness, history of malignancy or immunodeficiency, pregnancy, active tuberculosis, and recent receipt of blood products or a vaccine,"...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2003-07-02)
More Articles from Vaccine Weekly
- Pancreatic Cancer Vaccine
MnSOD expression after pancreatic cancer vaccination may be suppressive - Vaccine Adjuvant
Interleukins-2 and -4, but not interferon-gamma, exhibit adjuvant activity - Vaccine Delivery
Needle-free delivery of DNA vaccine increases immune responses - Cancer Vaccine
Antitumor immunity induced by electrofusion of tumor and dendritic cells - Dendritic Cell Vaccine
Cytomegalovirus-specific T cells stimulated using modified dendritic cells - Vaccine Delivery
Lipid core peptides provide novel self-adjuvanting vaccine delivery system - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
